I guess of most interest - although it's the basically the same wording from the annual report. But again mentions that Neuren is engaging with a US partner (presumably ACADIA)
'In February 2019, the board appointed Torreya, a global investment bank specialising in life science, as Neuren's corporate adviser to evaluate all potential corporate transactions, for individual products, defined territories, or Neuren's entire business. A formal process commenced in April and is presently underway, engaging with third parties in the US, Europe and Japan'.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |